Australia · Delayed Price · Currency is AUD Cambium Bio Statistics
Total Valuation
Cambium Bio has a market cap or net worth of AUD 14.72 million. The enterprise value is 13.75 million.
| Market Cap | 14.72M |
| Enterprise Value | 13.75M |
Important Dates
The last earnings date was Friday, September 4, 2026.
| Earnings Date | Sep 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Cambium Bio has 29.43 million shares outstanding. The number of shares has increased by 30.54% in one year.
| Current Share Class | 29.43M |
| Shares Outstanding | 29.43M |
| Shares Change (YoY) | +30.54% |
| Shares Change (QoQ) | +22.01% |
| Owned by Insiders (%) | 34.89% |
| Owned by Institutions (%) | n/a |
| Float | 3.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 12.01 |
| PB Ratio | 6.19 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 11.22 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.95, with a Debt / Equity ratio of 0.06.
| Current Ratio | 0.95 |
| Quick Ratio | 0.93 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.05 |
| Interest Coverage | -17,151.82 |
Financial Efficiency
Return on equity (ROE) is -194.37% and return on invested capital (ROIC) is -97.31%.
| Return on Equity (ROE) | -194.37% |
| Return on Assets (ROA) | -66.82% |
| Return on Invested Capital (ROIC) | -97.31% |
| Return on Capital Employed (ROCE) | -158.61% |
| Weighted Average Cost of Capital (WACC) | 3.40% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.35 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -0.99% in the last 52 weeks. The beta is -0.15, so Cambium Bio's price volatility has been lower than the market average.
| Beta (5Y) | -0.15 |
| 52-Week Price Change | -0.99% |
| 50-Day Moving Average | 0.43 |
| 200-Day Moving Average | 0.44 |
| Relative Strength Index (RSI) | 64.85 |
| Average Volume (20 Days) | 9,774 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cambium Bio had revenue of AUD 1.23 million and -4.10 million in losses. Loss per share was -0.17.
| Revenue | 1.23M |
| Gross Profit | 1.04M |
| Operating Income | -3.77M |
| Pretax Income | -4.10M |
| Net Income | -4.10M |
| EBITDA | -3.77M |
| EBIT | -3.77M |
| Loss Per Share | -0.17 |
Balance Sheet
The company has 1.12 million in cash and 149,804 in debt, with a net cash position of 966,363 or 0.03 per share.
| Cash & Cash Equivalents | 1.12M |
| Total Debt | 149,804 |
| Net Cash | 966,363 |
| Net Cash Per Share | 0.03 |
| Equity (Book Value) | 2.38M |
| Book Value Per Share | 0.09 |
| Working Capital | -72,986 |
Cash Flow
In the last 12 months, operating cash flow was -2.81 million and capital expenditures -2,638, giving a free cash flow of -2.81 million.
| Operating Cash Flow | -2.81M |
| Capital Expenditures | -2,638 |
| Depreciation & Amortization | 2,638 |
| Net Borrowing | -318,654 |
| Free Cash Flow | -2.81M |
| FCF Per Share | -0.10 |
Margins
| Gross Margin | 84.47% |
| Operating Margin | -307.87% |
| Pretax Margin | -334.20% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Cambium Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -30.54% |
| Shareholder Yield | -30.54% |
| Earnings Yield | -27.83% |
| FCF Yield | -19.09% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 4, 2024. It was a reverse split with a ratio of 0.01.
| Last Split Date | Jul 4, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.01 |
Scores
Cambium Bio has an Altman Z-Score of -16.72 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -16.72 |
| Piotroski F-Score | 4 |